Loading stock data…
$4.13-0.02 (-0.48%)
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
Quoin Pharmaceuticals, Ltd. in the Healthcare sector is trading at $4.13 with a market capitalization of $14M. Wall Street consensus targets $20.71 (7 analysts), implying a +401.6% move over the next 12 months. The stock is currently near its 52-week low of $3.25, remaining 37.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.47M↓ | -$5.13M↓ | -$4.52M↓ | -$4.02M↓ | -$3.79M |
| Net Income | -$5.37M↓ | -$5.00M↓ | -$4.35M↓ | -$3.95M↓ | -$3.70M |
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lo...